GlaxoSmithKline plc (LON:GSK) has been assigned a GBX 1,550 ($20.38) price objective by UBS AG in a research report issued to clients and investors on Tuesday. The firm presently has a “neutral” rating on the stock. UBS AG’s target price would indicate a potential upside of 2.18% from the stock’s previous close.

A number of other research firms also recently issued reports on GSK. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.98) price target on GlaxoSmithKline plc and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Jefferies Group LLC restated a “buy” rating and set a GBX 1,900 ($24.98) price target on shares of GlaxoSmithKline plc in a research note on Thursday, July 13th. Bryan, Garnier & Co restated a “neutral” rating and set a GBX 1,710 ($22.48) price target on shares of GlaxoSmithKline plc in a research note on Tuesday, September 19th. Deutsche Bank AG set a GBX 1,610 ($21.17) price target on GlaxoSmithKline plc and gave the stock a “neutral” rating in a research note on Thursday, September 21st. Finally, J P Morgan Chase & Co dropped their price target on GlaxoSmithKline plc from GBX 1,750 ($23.01) to GBX 1,570 ($20.64) and set a “neutral” rating on the stock in a research note on Wednesday, September 13th. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have issued a buy rating to the company’s stock. GlaxoSmithKline plc currently has an average rating of “Hold” and a consensus price target of GBX 1,689.48 ($22.21).

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1517.00 on Tuesday. The company’s 50 day moving average price is GBX 1,500.18 and its 200-day moving average price is GBX 1,586.54. GlaxoSmithKline plc has a 12-month low of GBX 1,444.00 and a 12-month high of GBX 1,724.50. The firm’s market cap is GBX 74.15 billion.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/10/12/glaxosmithkline-plc-gsk-pt-set-at-gbx-1550-by-ubs-ag.html.

In other news, insider Patrick Vallance acquired 861 shares of GlaxoSmithKline plc stock in a transaction that occurred on Friday, July 14th. The stock was purchased at an average cost of GBX 1,618 ($21.27) per share, with a total value of £13,930.98 ($18,315.78). Also, insider Manvinder Singh Banga acquired 2,267 shares of GlaxoSmithKline plc stock in a transaction that occurred on Wednesday, July 26th. The shares were purchased at an average cost of GBX 1,599 ($21.02) per share, with a total value of £36,249.33 ($47,658.86). Over the last ninety days, insiders have purchased 3,153 shares of company stock valued at $5,055,853.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.